ANTI-OSTEOPOROSIS DRUGS PRESCRIPTIONS AMONG OSTEOPOROSIS PATIENTS WITH T2DM IN CHINA
Author(s)
Mengyao Xue, BsC1, Shuo Zhang, BsC1, Nan Peng, PhD2, guoxian Lu, BsC1, Ruolan Wei, BsC1, Dongning Yao, PhD1;
1Nanjing Medical University, School of Pharmacy, Nanjing, China, 2School of Pharmaceutical Science and Technology,Tianjin University, Tianjin, China
1Nanjing Medical University, School of Pharmacy, Nanjing, China, 2School of Pharmaceutical Science and Technology,Tianjin University, Tianjin, China
OBJECTIVES: Osteoporosis and type 2 diabetes mellitus (T2DM) are both prevalent chronic diseases among the elderly, and the presence of T2DM may influence medication choices for osteoporosis. This study aims to clarify the trends and prescription patterns of osteoporosis medications among osteoporosis with T2DM in China.
METHODS: This study utilized data from a provincial-level medical big data platform in eastern China. Patients diagnosed with osteoporosis between January 2018 and October 2025 who had at least one prescription record for anti-osteoporosis medication were included. They were categorized into a DM group (with T2DM) and a non-DM group (without T2DM). The study assessed the utilization rates of each anti-osteoporosis medication and differences in prescribing patterns between the two groups.
RESULTS: A total of 657,132 osteoporosis patients were enrolled in this study, including 172,510 in the DM group and 484,622 in the non-DM group. Active vitamin D and its analogs were the most used anti-osteoporosis drugs in both groups, with a significantly higher utilization rate in the DM group. Except for this category, the utilization rates of all other anti-osteoporosis drugs were lower in the DM group than in the non-DM group. Monotherapy was the predominant treatment strategy for both groups, and the monotherapy prescription rate was higher in the DM group; the most common combination regimen was active vitamin D and its analogs plus bisphosphonates.
CONCLUSIONS: This study reveals the prescription patterns of osteoporosis patients with T2DM. Diabetes status significantly influences the selection of osteoporosis medications. Compared with the non-DM group, DM patients were more inclined to monotherapy, among which active vitamin D and its analogs were most frequently used, with less utilization of other classes of anti-osteoporotic drugs.
METHODS: This study utilized data from a provincial-level medical big data platform in eastern China. Patients diagnosed with osteoporosis between January 2018 and October 2025 who had at least one prescription record for anti-osteoporosis medication were included. They were categorized into a DM group (with T2DM) and a non-DM group (without T2DM). The study assessed the utilization rates of each anti-osteoporosis medication and differences in prescribing patterns between the two groups.
RESULTS: A total of 657,132 osteoporosis patients were enrolled in this study, including 172,510 in the DM group and 484,622 in the non-DM group. Active vitamin D and its analogs were the most used anti-osteoporosis drugs in both groups, with a significantly higher utilization rate in the DM group. Except for this category, the utilization rates of all other anti-osteoporosis drugs were lower in the DM group than in the non-DM group. Monotherapy was the predominant treatment strategy for both groups, and the monotherapy prescription rate was higher in the DM group; the most common combination regimen was active vitamin D and its analogs plus bisphosphonates.
CONCLUSIONS: This study reveals the prescription patterns of osteoporosis patients with T2DM. Diabetes status significantly influences the selection of osteoporosis medications. Compared with the non-DM group, DM patients were more inclined to monotherapy, among which active vitamin D and its analogs were most frequently used, with less utilization of other classes of anti-osteoporotic drugs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD117
Topic
Real World Data & Information Systems
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)